Clinical Trial Update: Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating the combination of temsirolimus (CCI-779) and bortezomib (Velcade) in relapsed or relapsed/refractory multiple myeloma; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-05-10